In this video, senior health-care analyst David Williamson discusses Abbott Labs' recent phase 2 hepatitis C drug results and how they are changing the perception of who will control this multibillion-dollar market. Watch and find out what lays ahead for Abbott, or more specifically its spinoff AbbVie, and the rest of the stocks racing to produce the best-in-class next-gen treatment.

Many investors are attracted to Amarin and biotechs like it since they hold the allure of substantial short-term gains. But there is more than one approach to building long-term wealth and retiring well. In our free report "3 Stocks That Will Help You Retire Rich," we reveal some stocks that could help you as well as some winning wealth-building strategies. Click here to keep reading.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium advisory service. We’re motley! Questioning an investing thesis -- even one of our own -- helps us all think critically about investing and make decisions that help us become smarter, happier, and richer.